In the first activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety considerations, and efficacy data of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for FcRn antagonist therapy, and apply an individualized approach to treatment planning based on available evidence and patient preferences.
Generalized myasthenia gravis (gMG) disrupts neuromuscular transmission, creating unpredictable symptom flare-ups and placing a significant burden on patients with this rare condition. Most commonly associated with antibodies targeting the acetylcholine receptor (AChR), and less commonly with muscle specific kinase (MuSK) or low-density lipoprotein receptor–related protein 4 (LRP4), gMG has forced patients and clinicians to navigate treatments that can be difficult to tolerate, slow to act, or limited by safety concerns. The expanding availability of neonatal Fc receptor (FcRn) blockers has introduced targeted options designed to reduce pathogenic IgG and improve symptoms. Clinicians, however, lack practical, evidence-based guidance on optimizing FcRn antagonist regimens in partial responders, including interval adjustments, transitions between cyclic and consistent dosing, structured monitoring, and safe steroid tapering, which results in persistent symptoms and avoidable treatment burden. Clinicians and multidisciplinary care teams require rigorous education in optimized dosing and longitudinal management to transform the care experience for patients with gMG.
In the second activity of this CME Outfitters BriefCase series, expert faculty will differentiate MOAs, safety, and efficacy profiles of currently approved FcRn antagonists for the treatment of gMG. Faculty will incorporate strategies to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists, and utilize an individualized approach to treatment planning for patients with gMG receiving FcRn antagonists based on the latest data as well as patient preferences.
In this CME Outfitters BriefCase, expert faculty will identify how the complex, Th2-driven pathophysiology of EoE impacts diagnosis and treatment and integrate evidence-based treatments into the care of patients with EoE based on clinical trial data. Faculty will model development of long-term care plans for patients with EoE to address the chronic, progressive nature of this disease.
In this CME Outfitters BriefCase, expert faculty will utilize real-world case studies to explore gaps in clinician and patient adherence to the MREMS, including discussions and/or demonstrations of counseling, pregnancy testing, acceptable contraception methods, and monitoring of confirmed pregnancies via the Mycophenolate Pregnancy Registry to support ongoing pharmacovigilance.
In this CME Outfitters BriefCase, expert faculty will use case examples to highlight the current clinical guidelines for biomarker testing and advise learners on addressing ethnic, geographic, and socioeconomic barriers to optimal utilization of biomarker testing in lung cancer.
In this CME Outfitters BriefCase, expert faculty will discuss the impact of implicit bias and structural inequities on referral patterns, access to bariatric surgery, and postoperative outcomes across diverse patient populations, as well as evidence-based approaches to reduce disparities in bariatric surgery.
